Ardelyx, Inc. (NASDAQ:ARDX) – Analysts at Cantor Fitzgerald issued their FY2016 earnings per share (EPS) estimates for shares of Ardelyx in a note issued to investors on Tuesday. Cantor Fitzgerald analyst M. Goldstein expects that the brokerage will post earnings of ($2.85) per share for the year. Cantor Fitzgerald also issued estimates for Ardelyx’s FY2017 earnings at ($3.13) EPS.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.09.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of US & international copyright laws. The correct version of this news story can be read at http://www.watchlistnews.com/ardelyx-inc-ardx-expected-to-post-fy2016-earnings-of-2-85-per-share/1061133.html.

Earnings History and Estimates for Ardelyx (NASDAQ:ARDX)

A number of other research firms have also weighed in on ARDX. Leerink Swann set a $18.00 target price on shares of Ardelyx and gave the stock a “buy” rating in a research report on Sunday, November 20th. Zacks Investment Research raised shares of Ardelyx from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research report on Tuesday, October 11th. Finally, Wedbush reaffirmed an “outperform” rating and set a $24.00 price objective on shares of Ardelyx in a research report on Friday, January 6th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Ardelyx currently has an average rating of “Buy” and an average target price of $19.13.

Ardelyx (NASDAQ:ARDX) opened at 14.70 on Friday. The firm’s market capitalization is $695.32 million. The stock’s 50 day moving average price is $14.76 and its 200 day moving average price is $12.13. Ardelyx has a 12 month low of $6.36 and a 12 month high of $16.30.

Hedge funds and other institutional investors have recently bought and sold shares of the company. American International Group Inc. raised its position in Ardelyx by 36.8% in the second quarter. American International Group Inc. now owns 13,176 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 3,544 shares during the period. Highbridge Capital Management LLC acquired a new position in Ardelyx during the second quarter valued at about $129,000. Citadel Advisors LLC acquired a new position in Ardelyx during the third quarter valued at about $134,000. Wedbush Securities Inc. acquired a new position in Ardelyx during the third quarter valued at about $149,000. Finally, Great Point Partners LLC acquired a new position in Ardelyx during the third quarter valued at about $194,000. 81.55% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of US & international copyright laws. The correct version of this news story can be read at http://www.watchlistnews.com/ardelyx-inc-ardx-expected-to-post-fy2016-earnings-of-2-85-per-share/1061133.html.

Ardelyx Company Profile

Ardelyx, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment.

5 Day Chart for NASDAQ:ARDX

Receive News & Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.